Floatz logo

Irinotecan

Relapsed or Refractory Pediatric Malignant Solid Tumors (Including Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma)

Tianjin Medical University Cancer Institute and HospitalSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

32 Active assets in the Relapsed or Refractory Pediatric Malignant Solid Tumors (Including Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma) cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Tianjin Medical University Cancer Institute and Hospital
Phase 2BB
Cyclophosphamide
St. Jude Children's Research Hospital
Phase 2BB
Nivolumab
Australian & New Zealand Children's Haematology/Oncology Group
Phase 2B
OTL-38
Mayo Clinic
Phase 3B
Irinotecan
Australian & New Zealand Children's Haematology/Oncology Group
Phase 1/2B

View all 50 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →